Ipamorelin

Ipamorelin pairs a clean, well-understood mechanism with an almost empty human outcomes file. If you want a selective growth-hormone secretagogue, accept that the popular benefits are unproven in people, and can monitor IGF-1 and glucose with quality material, it is a reasonable, low-drama tool. If you expect evidence-backed fat loss or recovery, the data is not there, and the one human efficacy trial failed, per Beck 2014. The biggest real-world risk is not the molecule; it is sourcing unregulated peptides.

✅ Best for: Researchers and clinicians who value receptor selectivity and a mild side-effect profile over proven outcomes. Older adults with low baseline growth-hormone output, who tend to respond more. People chasing the most consistently reported effect, better sleep, who will judge it on their own response over a few weeks. Users who already have training, protein, and sleep dialed in and want a low-suppression add-on. Anyone who can obtain pharmaceutical-grade material with a third-party certificate of analysis and will track IGF-1 and fasting glucose.

❌ Avoid if: You have active or hormone-sensitive cancer, since growth-hormone and IGF-1 signaling can promote proliferation. You are pregnant or breastfeeding, with no safety data. You have uncontrolled diabetes or insulin resistance, because growth hormone opposes insulin. You have congestive heart failure or fluid-overload risk. You compete in tested sport, since secretagogues are banned at all times under WADA S2. You cannot verify source quality, because contamination and immunogenicity from aggregated research-chemical peptides may exceed the intrinsic pharmacological risk.